Biodeal Pharmaceuticals secures INR 3.85 billion investment from RMB Capitalworks for global scale-up

Biodeal Pharmaceuticals has secured an INR 3.85 billion growth capital investment from joint venture private equity entity RMB Capitalworks. The funds will fuel international manufacturing expansion across CIS, Latin American, European, and Asian markets, following a successful venture exit by Piramal Alternatives.

Biodeal Pharmaceuticals has secured an INR 3.85 billion investment from RMB Capitalworks, a joint venture partnership formed by Rand Merchant Bank and Capitalworks Group.

Headquartered in Noida, Uttar Pradesh, Biodeal Pharmaceuticals is a contract development and manufacturing organization focused on nasal drug delivery systems, complex generics, and specialty formulations. The company runs two WHO-GMP certified facilities and supplies over 1,000 pharmaceutical partners across 80 international markets.

The newly secured capital is earmarked for global manufacturing and distribution expansion, targeting high-growth medical regions across the Commonwealth of Independent States, Latin America, Europe, and Asia. This growth strategy aims to scale production capacities to meet accelerating international demand for complex drug delivery systems and specialized generic products.

For global healthcare markets and institutional investors, the transaction highlights sustained private equity confidence in specialized pharmaceutical manufacturing outsourcing within India. Private capital inflows into advanced drug delivery and specialized formulation sectors underline a broader movement toward securing resilient cross-border pharmaceutical supply chains.